Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2021-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年半年度报告" which translates to "2021 Half-Year Report". It contains detailed financial data for the period January 1, 2021 to June 30, 2021, including revenue, net profit, cash flow, and other financial indicators. It also includes management discussion and analysis, company overview, risk factors, governance, and other comprehensive sections typical of an interim or quarterly report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of unaudited financial statements and detailed management commentary confirms it is an Interim / Quarterly Report. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2021
2021-08-27 Chinese
成都先导药物开发股份有限公司关于召开2021年半年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2021 half-year performance explanation meeting (业绩说明会) for Chengdu Lead Drug Development Co., Ltd. It mentions the date, time, location, and format of the meeting, as well as instructions for investors to submit questions. The document references the 2021 half-year report but does not contain the report itself or detailed financial data. The length is short (1386 characters), and it serves as a notice for an upcoming investor presentation event rather than the presentation or report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or a notice about the meeting. However, since it is primarily an announcement of the meeting for discussing the half-year results and not the presentation materials themselves, it aligns with the Investor Presentation (IP) category, which includes detailed presentations for investors focusing on financials, strategy, and market position, or announcements related to such presentations. Given the content, the best fit is Investor Presentation (IP).
2021-08-27 Chinese
成都先导药物开发股份有限公司独立董事关于第一届董事会第十七次会议相关议案的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on a specific board meeting agenda item related to the company's 2021 half-year fundraising funds storage and usage report. It references regulatory guidelines and confirms compliance but does not contain full financial statements or detailed financial data. The document is short (854 characters) and serves as an opinion or certification rather than a full report. It is not an Annual Report, Interim Report, or Audit Report. It is also not a general regulatory filing or announcement of a report publication. The content fits best under Regulatory Filings (RNS) as it is a compliance-related independent opinion on a specific agenda item without substantive financial data or full report content.
2021-08-27 Chinese
成都先导药物开发股份有限公司关于2021年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by Chengdu Lead Drug Development Co., Ltd. It details the management, storage, and actual usage of funds raised through a public stock issuance in 2020. The report includes specific financial figures on the raised funds, their allocation, usage, and investment projects, as well as compliance with regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The document is a specialized report focusing on the use of capital raised by the company, not a general financial report or earnings release. It fits the category of Capital/Financing Update (CAP) because it provides an update on the company's fundraising and the use of those funds, including regulatory compliance and investment details. The document length (5822 characters) and detailed financial data support this classification rather than a simple announcement or regulatory filing.
2021-08-27 Chinese
成都先导药物开发股份有限公司第一届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Chengdu Lead Drug Development Co., Ltd. It details the meeting date, attendance, and voting results on several agenda items, including approval of the 2021 semi-annual report, a special report on the use of raised funds, approval of cross-border fund pool settlement business, and approval of mortgage loan for office land use rights. The document references other detailed reports and announcements published on the Shanghai Stock Exchange website but does not contain the full semi-annual report or detailed financial statements itself. The document length is short (1672 characters) and serves as an official announcement of meeting resolutions and approvals rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as the semi-annual report (IR) or other specific report types.
2021-08-27 Chinese
成都先导药物开发股份有限公司关于持股5%以上股东减持计划减持时间过半的公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement about the progress of a shareholding reduction plan by shareholders holding more than 5% of the company's shares. It includes specific data on shareholding percentages, reduction quantities, dates, and methods of share reduction. The document does not contain financial statements or performance data but focuses on the disclosure of shareholding changes by major shareholders. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document is not an annual report, earnings release, or any other financial report type, nor is it a regulatory filing or a report publication announcement. Therefore, the correct classification is MRQ with high confidence.
2021-08-11 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.